Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. (Nasdaq: MGNX) is a biopharmaceutical company that publicly describes its focus as discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The MGNX news page on Stock Titan aggregates company-issued updates and third-party coverage so readers can follow how MacroGenics communicates progress across its oncology pipeline, technology platforms and collaborations.
In its press releases, MacroGenics highlights clinical developments for programs such as lorigerlimab, a bispecific PD‑1 × CTLA‑4 DART® molecule, and a portfolio of antibody-drug conjugates including MGC026, MGC028 and MGC030. News items also describe partnered programs like MGD024 with Gilead Sciences, ZYNYZ® (retifanlimab-dlwr) with Incyte and TZIELD® (teplizumab-mzwv) associated with Sanofi, including milestone structures and royalty arrangements disclosed by the company.
MacroGenics regularly issues announcements on quarterly financial results, cash runway expectations, royalty purchase agreements and other financing-related transactions. Additional news covers participation in healthcare and investment conferences, leadership changes such as the appointment of a new President and Chief Executive Officer, and updates on strategic priorities for advancing its antibody-based oncology portfolio and technology platforms.
Investors and observers who follow MGNX news can use this page to review how MacroGenics reports progress in its clinical trials, describes its collaborations and outlines its financial position in official communications. Bookmarking the news feed provides a centralized view of press releases and related information that the company files or references in its SEC disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on antibody-based cancer therapies, announced its management's participation in several upcoming investor conferences. Key events include:
- Stifel 2023 Targeted Oncology Days: Presentation by Scott Koenig on April 26, 2023, at 2:00 pm ET.
- H.C. Wainwright BioConnect Investor Conference: Fireside chat with Scott Koenig on May 2, 2023, at 1:00 pm ET.
- JMP Securities Life Sciences Conference: Fireside chat with Scott Koenig on May 15, 2023, at 9:30 am ET.
Investors can access webcasts of these presentations in the Investor Relations section of MacroGenics' website, with archived replays available for 30 days. The company utilizes advanced antibody technology to develop innovative therapeutics.
MacroGenics, Inc. (NASDAQ: MGNX) announced a $15 million milestone payment from Incyte following FDA approval of ZYNYZ™ (retifanlimab-dlwr), a monoclonal antibody for treating Merkel cell carcinoma. Originally developed by MacroGenics and licensed to Incyte in October 2017, ZYNYZ's approval marks the third product launch from MacroGenics' pipeline. Additionally, MacroGenics stands to gain up to $320 million in remaining development and regulatory milestones, $330 million in commercial milestones, and a 15% to 24% royalty on global net sales. The CEO expressed satisfaction over this development, highlighting its significance for patient treatment options.